InformedDNA, a leading precision health company, has acquired Philadelphia-based Coriell Life Sciences, a provider of pharmacogenomic services and clinical decision support. The strategic acquisition, announced on March 19, 2025, aims to expand patient, provider, and payor access to genetic insights while enabling more personalized treatment and medication decisions.
The combination brings together InformedDNA's expertise in genetic test interpretation and counseling with Coriell Life Sciences' specialization in pharmacogenomics—the study of how genes affect an individual's response to medication. This integration is expected to drive better patient outcomes and reduce healthcare costs through more targeted therapeutic approaches.
Strategic Integration Already Underway
The companies have already begun working together by integrating Coriell's pharmacogenomic services into DNAimpact™, InformedDNA's precision health platform. This combined offering identifies more effective therapies based on patients' genomic profiles while providing interactive education and access to clinical experts.
"The combination of our companies is a transformative step forward in the future of precision medicine," said Scott Megill, CEO of Coriell Life Sciences, who will now serve as Chief Commercial Officer for InformedDNA. "By uniting our expertise in pharmacogenomics and clinical decision support with InformedDNA's industry-leading genetic test interpretation and counseling services, we are creating an unparalleled resource for patients, providers, and health organizations."
Expanding Precision Medicine Access
Coriell Life Sciences, which was founded in 2013 as a spin-out from the Coriell Institute for Medical Research, brings valuable assets to the partnership. Its flagship product, Corigen®, is a population-scale medication risk management program that helps health plans, employers, health systems, and pharmacy benefits managers ensure patients receive the most appropriate medications. The company also provides expert pharmacogenomic research analysis for laboratories.
Dr. Surya Singh, CEO of InformedDNA, highlighted the strategic importance of the acquisition: "Pharmacogenomics is a critical aspect of personalized precision healthcare, and it presents an important opportunity to expand our ability to drive better patient outcomes. Looking across the pharmacogenomics space, Coriell Life Sciences stands out for its extensive collaboration with leading laboratories that specialize in genetic and complex molecular testing."
Addressing Underserved Markets
A key benefit of the acquisition is InformedDNA's expanded reach into public employer plans, which Dr. Singh noted are "currently underserved by precision medicine." Coriell Life Sciences brings experience working with a broad selection of employer plan sponsors, opening new market opportunities.
InformedDNA, which boasts the largest independent staff of board-certified genetics specialists in the U.S., has spent nearly two decades building expertise in genetics and developing innovative technology. The company provides telegenetic counseling to patients across all 50 states and has been implementing programs like DNAimpact™ to integrate digital-first patient engagement tools with proactive population care management in areas such as oncology, maternity, and polypharmacy.
Future Impact on Healthcare
The acquisition represents a significant advancement in the application of genomics to everyday healthcare decisions. By combining Coriell's six decades of scientific expertise in bridging the gap between genetic knowledge and clinical application with InformedDNA's established infrastructure, the merged entity aims to make precision medicine more accessible and practical.
The integration of pharmacogenomics into standard care has the potential to significantly reduce adverse drug reactions, improve medication efficacy, and optimize treatment plans based on individual genetic profiles. This patient-specific approach aligns with the broader healthcare industry shift toward more personalized medicine and value-based care models.
As healthcare continues to evolve toward more personalized approaches, this acquisition positions the combined company to play a leading role in shaping how genetic information is used to inform clinical decisions and improve patient care across multiple therapeutic areas.
